3 Integrated Energy Stocks to Gain Despite Industry Vulnerability
Among the companies in the industry that will probably survive the business challenges are Exxon Mobil Corporation XOM, Chevron Corporation CVX and Shell plc SHEL.
About the Industry
The Zacks Oil and Gas Integrated International industry covers companies primarily involved in upstream, midstream and downstream operations. These companies have upstream businesses in the United States (including prolific shale plays and the deepwater Gulf of Mexico), Asia, South America, Africa, Australia and Europe. Midstream operations of energy companies entail transporting oil, natural gas liquids and refined petroleum products.
In downstream businesses, the firms buy raw crude to produce refined petroleum products. The companies' downstream activities involve chemical businesses that manufacture raw materials for making plastics. The integrated players are now gradually focusing on renewables, leading to the energy transition. The firms aim to lower emissions from operations and cut the carbon intensity of the products sold.
3 Trends Shaping the Future of the Industry
Macroeconomic Volatility: The integrated energy sector is currently navigating a highly uncertain and challenging macroeconomic environment. Refining, renewable energy and chemical segments are particularly under pressure due to limited visibility into future market dynamics. Escalating trade tensions are compounding this uncertainty, raising concerns over potential economic slowdowns. Meanwhile, oil prices remain volatile, swayed by geopolitical risks and fluctuating OPEC+ production strategies. As a result, major integrated energy players are grappling with profitability challenges.
Slowdown in Production Growth to Hurt Upstream Business: There has been a slowdown in oil production growth in the upstream businesses of integrated energy companies in the United States due to shareholder demands for a greater focus on returning capital rather than investing in production expansion. As production growth slows, output decreases, which can lead to reduced revenues. Since upstream operations depend heavily on volume to generate income, any stagnation in production growth has a direct and negative impact on their bottom line.
Growing Demand for Renewables is Concerning: Governments, investors and stakeholders are placing growing emphasis on addressing climate change, leading to an increased demand for renewable energy. Consequently, the demand for products reliant on oil, natural gas and natural gas liquids is expected to decline, with solar and wind energy gaining prominence in the energy landscape. The integrated energy firms are adversely impacted by these trends as they are primarily engaged in the production and transportation of fossil fuels, such as oil, and the sale of refined petroleum products.
Zacks Industry Rank Indicates Bearish Outlook
The Zacks Oil and Gas Integrated International industry is part of the broader Zacks Oil - Energy sector. It carries a Zacks Industry Rank #189, which places it in the bottom 23% of the 245 Zacks industries.
The group's Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates bleak near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Before we present a few stocks that you may want to consider, let us take a look at the industry's recent stock market performance and valuation picture.
Industry Lags S&P 500 & Sector
The Zacks Oil and Gas Integrated International industry has underperformed the broader Zacks Oil - Energy sector and the Zacks S&P 500 composite over the past year.
The industry has plunged 5.4% over this period compared with the S&P 500's growth of 17.3% and the broader sector's decline of 2.6%.
One-Year Price Performance
Industry's Current Valuation
Since oil and gas companies are debt-laden, it makes sense to value them based on the Enterprise Value/Earnings before Interest Tax Depreciation and Amortization (EV/EBITDA) ratio. This is because the valuation metric takes not just equity into account but also the level of debt.
On the basis of the trailing 12-month EV/EBITDA, the industry is currently trading at 4.27X, lower than the S&P 500's 17.85X. It is also below the sector's trailing 12-month EV/EBITDA of 4.77X.
Over the past five years, the industry has traded as high as 6.54X and as low as 2.75X, with a median of 4.11X.
Trailing 12-Month Enterprise Value-to EBITDA (EV/EBITDA) Ratio
3 Integrated International Stocks to Watch
Chevron: The company completed its $53-billion acquisition of Hess Corporation, thereby strengthening its upstream portfolio and obtaining a 30% interest in the highly valued Stabroek Block offshore Guyana. Chevron gains strategic access to one of the most prolific deepwater discoveries of the past decade, estimated to hold more than 11 billion barrels of recoverable oil. The acquisition also strengthens its position in the U.S. Bakken shale, the Gulf of Mexico and Southeast Asia. It currently carries a Zacks Rank #3 (Hold).
The move comes as a turning point for Chevron as it is facing mounting pressure to replenish its reserves and strengthen free cash flow amid ongoing volatility in the oil markets.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Price and Consensus: CVX
ExxonMobil: The company's acquisition of Pioneer Natural Resources expanded its production capabilities in the Permian Basin, one of the most profitable regions in the United States due to its inexpensive production costs. XOM boasts a strong portfolio of upstream assets, focused on oil-rich resources in the Permian Basin and offshore Guyana. Production costs in those assets are low. Therefore, the leading integrated energy major can overcome a collapse in oil and gas prices. Similar to its operations in the Permian, ExxonMobil boasts a robust project pipeline in offshore Guyana resources. It presently carries a Zacks Rank #3.
Price and Consensus: XOM
Shell: The company's acquisition of Pavilion Energy strengthens its LNG trading capabilities and positions itself for long-term growth in cleaner fuels. Shell's position as a major supplier of LNG should help the company meet the fuel's growing demand and improve its cash flow. Shell, with a Zacks Rank of 3, is targeting a 4-5% annual increase in LNG sales over the next five years and 1% annual production growth.
Price and Consensus: SHEL
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exxon Mobil Corporation (XOM): Free Stock Analysis Report
Chevron Corporation (CVX): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Microstrategy's Earnings Call: Positive Outlook Amid Challenges
Microstrategy ((MSTR)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Microstrategy's Earnings Call: A Positive Outlook Amid Challenges The recent earnings call from Microstrategy painted a picture of robust financial performance and strategic progress, despite some underlying challenges. The company showcased significant achievements in Bitcoin holdings, market capitalization growth, and the introduction of innovative financial products. While potential market risks and regulatory uncertainties were acknowledged, the overall sentiment remained positive, driven by strong financial results and strategic advancements. Record Bitcoin Holdings Microstrategy has solidified its position as a dominant player in the Bitcoin Treasury Company space, with a record holding of 628,791 Bitcoin. This accounts for 3% of all Bitcoin ever to exist, underscoring the company's aggressive strategy in cryptocurrency accumulation. Market Capitalization Milestone The company reached a significant milestone with its market capitalization surpassing $112 billion, making it the 96th largest public company in the United States. This achievement highlights Microstrategy's growing influence and stature in the financial markets. Significant Capital Raising In a remarkable financial feat, Microstrategy raised $18.3 billion in capital year-to-date, which is 81% of the total capital raised in the previous year, achieved in just seven months. This capital influx is expected to fuel further strategic investments and growth. Record EPS and Net Income Microstrategy reported a record EPS of $32.60 per share for Q2, alongside $14 billion in GAAP operating income and $10 billion in net income. These figures represent the highest in the company's history, reflecting strong operational performance. Introduction of Bitcoin Per Share (BPS) Metric The company introduced a new metric, Bitcoin Per Share (BPS), with a year-to-date figure of 39,716 Satoshis as of July 31. This metric is close to 60% of what was achieved last year, highlighting the company's strategy to consistently accumulate more Bitcoin per share. BTC Yield and Gain Microstrategy achieved a BTC Yield of 25% year-to-date and a BTC Gain of 111,894 Bitcoin. These metrics demonstrate the company's effective management and strategic use of its Bitcoin holdings. Successful Adoption of Fair Value Accounting The adoption of FASB's fair value accounting rule added $17.9 billion to the Bitcoin balance sheet and increased stockholders' equity by $12.7 billion. This move reflects Microstrategy's commitment to transparency and accurate financial reporting. Innovative Financial Products Microstrategy launched several innovative financial products, including STRF, STRK, STRD, and STRC, with STRC being the largest IPO in the U.S. this year. These products are expected to enhance the company's market offerings and drive future growth. Potential Market Risks The earnings call addressed concerns about the concentration of Bitcoin holdings at a single corporation, which could impede adoption. Additionally, the risk factors associated with Bitcoin price fluctuations were highlighted as potential challenges. Regulatory Uncertainty Microstrategy emphasized the need for more clarity on digital assets taxonomy and regulation to fully realize the potential of the crypto industry. Regulatory uncertainty remains a significant hurdle for the company's strategic ambitions. Volatility and Market Perception Despite its strong performance, Microstrategy is perceived as undervalued and misunderstood in the market, with a low P/E multiple compared to peers. This perception challenges the company's market valuation and investor sentiment. Forward-Looking Guidance Looking ahead, Microstrategy has set ambitious targets, including achieving a BTC Yield percentage of 30% and a BTC $ Gain of $20 billion by the end of the year. The company anticipates a GAAP operating income of $34 billion, net income of $24 billion, and an EPS of $80, assuming a Bitcoin price of $150,000. The capital plan involves transitioning from convertible bonds to preferred equity, aiming to increase leverage responsibly while maintaining robust collateral coverage. In summary, Microstrategy's earnings call reflects a positive outlook driven by record financial performance and strategic initiatives. Despite challenges such as market risks and regulatory uncertainties, the company's achievements in Bitcoin holdings, market capitalization, and innovative product offerings underscore its potential for future growth and success.
Globe and Mail
an hour ago
- Globe and Mail
BP Earnings Call: Strong Gains Amid Challenges
BP plc. ((BP)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. BP's Earnings Call Reflects Strong Performance Amid Challenges BP's recent earnings call conveyed a generally positive sentiment, underscored by robust operational performance and significant exploration successes. The company reported increased earnings, successful divestments, cost reductions, and enhanced shareholder returns. However, challenges persist in certain segments, such as tight diesel margins and impairments in specific areas. Strong Upstream Performance BP showcased its strong upstream performance by bringing five new major oil and gas projects online and sanctioning four additional ones. The company also celebrated ten exploration discoveries, marking a remarkable year for discoveries, with the Bumerangue Block in Brazil standing out despite concerns over CO2 content. Increase in Underlying Earnings The earnings call highlighted a substantial increase in underlying earnings within BP's customers' business, which rose by approximately 50% compared to the previous year. This growth occurred despite challenging market conditions, showcasing BP's resilience and strategic prowess. Successful Divestments and Cost Reductions BP reported successful divestments, with expected proceeds reaching around $3 billion for the year. Additionally, the company achieved structural cost reductions of approximately $1.7 billion since early 2024, demonstrating its commitment to financial efficiency. Dividend Increase and Share Buyback Shareholders were pleased with BP's announcement of a dividend increase of 4% to $0.0832 per ordinary share. Furthermore, the company declared a $750 million share buyback for the second quarter, reinforcing its commitment to returning value to shareholders. Record Refining Availability BP achieved record refining availability of 96.4% for the quarter, the highest since 2006. This milestone reflects the company's operational excellence and ability to maintain high levels of efficiency. Challenging Diesel Margins Despite the positive developments, BP faced challenges with tight diesel margins in its TravelCenters of America business, which impacted profitability. This segment remains an area of concern for the company. Impairments in Customer and Products and Gas and Low Carbon Segments BP took several impairments related to decisions on hydrogen and biofuels projects in Australia, as well as in the gas and low carbon space concerning M&S. These impairments highlight the ongoing challenges in these segments. Forward-Looking Guidance Looking ahead, BP's guidance remains optimistic, with operational reliability reported at over 96% across both upstream and downstream sectors. The company is committed to its 12-quarter strategic plan, focusing on enhancing operational efficiency and shareholder value. BP aims to continue its momentum with new projects and exploration discoveries, despite the challenges in certain areas. In conclusion, BP's earnings call painted a picture of a company achieving strong operational and financial performance, while also navigating challenges in specific segments. The overall sentiment was positive, with significant achievements in exploration and shareholder returns, although certain areas require continued attention and improvement.
Globe and Mail
2 hours ago
- Globe and Mail
Chronic Lymphocytic Leukemia Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Chronic Lymphocytic Leukemia Pipeline Insight 2025' report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Chronic Lymphocytic Leukemia Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Chronic Lymphocytic Leukemia Pipeline Outlook Report In July 2025, AstraZeneca announced a Phase IV study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally [po], twice daily [bd]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of < 50%. In July 2025, BeiGene announced a study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax. In July 2025, AbbVie conducted a study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 120 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. DelveInsight's Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment. The leading Chronic Lymphocytic Leukemia Companies such as Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Promising Chronic Lymphocytic Leukemia Therapies such as Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Discover how the Chronic Lymphocytic Leukemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Lymphocytic Leukemia Clinical Trials and Studies Chronic Lymphocytic Leukemia Emerging Drugs Profile Pirtobrutinib: Loxo Oncology Pirtobrutinib is an investigational, oral, highly-selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor, signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia. Cirmtuzumab: Oncternal Therapeutics Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 in conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL. MS-553: MingSight Pharmaceuticals MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKCβ, a signaling molecule immediately downstream of BTK and PLCγ2 in the B-cell receptor (BCR) pathway. As PKCβ is downstream of both BTK and PLCγ2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKCβ signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of CLL. NX-2127: Nurix Therapeutics NX-2127 is an oral small molecule that combines the activity of a targeted BTK degrader with the cereblon immunomodulatory activity of an IKZF degrader. Cereblon immunomodulatory drugs that induce degradation are IKZF1 and IKZF3. Preclinical data support the activity of NX-2127 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to FDA-approved agents. Studies in non-human primates confirm potent BTK degradation with once-daily oral dosing. NX-2127 is being tested in an ongoing Phase I trial for patients with chronic lymphocytic leukemia who have failed prior treatments. NX-5948: Nurix Therapeutics NX-5948 is an oral small molecule degrader of BTK. Preclinical data support the activity of NX-5948 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to leading FDA approved agents. NX-5948 lacks cereblon immunomodulatory activity and has demonstrated the ability to cross the blood-brain barrier in animal models. NX-5948 has also demonstrated activity in animal models of autoimmune disease. The drug is currently being evaluated in the Phase I stage of development for the treatment of chronic lymphocytic leukemia. The Chronic Lymphocytic Leukemia Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment. Chronic Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market Explore groundbreaking therapies and clinical trials in the Chronic Lymphocytic Leukemia Pipeline. Access DelveInsight's detailed report now! @ New Chronic Lymphocytic Leukemia Drugs Chronic Lymphocytic Leukemia Companies Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Chronic Lymphocytic Leukemia Pipeline Report Coverage- Global Chronic Lymphocytic Leukemia Companies- Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic Lymphocytic Leukemia Therapies- Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Chronic Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Chronic Lymphocytic Leukemia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Chronic Lymphocytic Leukemia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Chronic lymphocytic leukemia: Overview Pipeline Therapeutics Therapeutic Assessment Chronic lymphocytic leukemia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Pirtobrutinib: Loxo Oncology Drug profiles in the detailed report….. Mid Stage Products (Phase II) Cirmtuzumab: Oncternal Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) NX-2127: Nurix Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Chronic lymphocytic leukemia Key Companies Chronic lymphocytic leukemia Key Products Chronic lymphocytic leukemia- Unmet Needs Chronic lymphocytic leukemia- Market Drivers and Barriers Chronic lymphocytic leukemia- Future Perspectives and Conclusion Chronic lymphocytic leukemia Analyst Views Chronic lymphocytic leukemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
